عنوان الدراسة | الجهاز | رقم البروتوكول | الراعي | الحالة | موقع الدراسة |
---|---|---|---|---|---|
Randomized, three-way, three-period, single oral dose, open-label, crossover, bioequivalence study to compare Lipomax tablets (20 mg atorvastatin) Produced by SAJA / KSA, versus Lipitor® tablets (20 mg atorvastatin) Produced by Pfizer / | Nov-17 |
SFDA |
جاري | Saudi Ajal | |
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Pedovex film-coated tablets (75 mg clopidogrel) Produced by Tabuk / KSA versus Plavix® film-coated tablets (75 mg clopid | Oct-17 |
SFDA |
جاري | Saudi Ajal | |
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Biscor film-coated tablets (10 mg bisoprolol fumarate) Produced by Pharma International / Jordan versus Concor® film-coated tablets (10 | Sep-17 |
SFDA |
جاري | Saudi Ajal | |
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Arena film-coated tablets (150 mg irbesartan) Produced by Jamjoom/ KSA versus Aprovel® film-coated tablets (150 mg irbesartan) Produced by | Aug-17 |
SFDA |
جاري | Saudi Ajal | |
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Capocard tablets (25 mg captopril) Produced by Dar AlDawa / Jordan versus Capoten® tablets (25 mg captopril) Produced by SPI | Jul-17 |
SFDA |
جاري | Saudi Ajal | |
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Angiotec tablets (20 mg enalapril) Produced by JPM / Jordan versus Renitec® tablets (20 mg enalapril) Produced by Merck Sharp & Dohme / UK, | Jun-17 |
SFDA |
جاري | Saudi Ajal | |
"A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or T | D5134C00003 |
AstraZeneca |
جاري | King Fahad Medical City (Riyadh) | |
"CAIN457A3404-REALIA A non-interventional, prospective 12-months study to characterize the REAL-life effectiveness and treatment patterns of SecukInumab and current standard of care in patient with chronic plaque psoriAsis eligible for systemic treatme |
IN457A3404 | Novartis |
جاري | King Khalid University Hospital (Riyadh) | |
ChaRactErization of patients following aCute venous thrOmboembolism (VTE) and assessment of safety and effectiveness of dabigatran etexilate (DE) in the tReatment and secondarY prevention of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) in | 1160.188 | Boehringer Ingelheim | جاري | King Salman Bin AbdulAziz Hospital | |
An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor positive (HR+) HER2-negative (HER2-) advanced | CLEE011A2404 | Novartis | جاري | King Abdulaziz Medical City NG (Riyadh) |